Finance

Lists
QTTB:NASDAQ
Q32 Bio Inc
$8.71
-1.25%
(-0.11) 1D
$8.71
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QTTB...
Open
$8.83
High
$8.95
Low
$8.45
Mkt. cap
260.64M
Avg. vol.
561.50K
Volume
243.85K
P/E ratio
2.61
52-wk high
$23.57
52-wk low
$1.90
EPS
$3.33
Beta
0.45
Shares outstanding
29.92M
No. of employees
25
Open
$8.83
High
$8.95
Low
$8.45
Mkt. cap
260.64M
Avg. vol.
561.50K
Volume
243.85K
P/E ratio
2.61
52-wk high
$23.57
52-wk low
$1.90
EPS
$3.33
Beta
0.45
Shares outstanding
29.92M
No. of employees
25
News stories
From web sources and news partners
About Q32 Bio Inc
CEO-
Employees25
Founded2017
HeadquartersWaltham, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websiteq32bio.com
Analyst ratings
Based on 7 analysts giving stock ratings to QTTB in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for QTTB in the last 3 months.
Highest
Current $8.71
$59.00 (+577.38%)
Average
$39.43 (+352.70%)
Lowest
$29.00 (+232.95%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Leerink Partners
Buy
Reiterated
$40.00
+359.2%
11/05/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$34.00
+290.4%
11/05/2026
Jay Olson
Oppenheimer
Buy
Maintained
$40.00
+359.2%
11/05/2026
Derek Archila
Wells Fargo
Buy
Maintained
$59.00
+577.4%
11/05/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$36.00
+313.3%
11/04/2026
Will Soghikian
Leerink Partners
Buy
Initiated
$40.00
+359.2%
10/12/2026
Maury Raycroft
Jefferies
Buy
Maintained
$29.00
+233%
10/01/2026
Kaveri Pohlman
Clear Street
Buy
Initiated
$38.00
+336.3%
10/01/2026
Judah Frommer
Morgan Stanley
Buy
Initiated
$34.00
+290.4%
08/24/2026
Joseph Catanzaro
Mizuho Securities
Buy
Reiterated
$36.00
+313.3%
07/13/2026
Richard Poland
Wells Fargo
Hold
Maintained
$10.00
+14.8%
05/28/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
$10.00
+14.8%
05/28/2026
Unknown Analyst
Cantor Fitzgerald
Buy
Initiated
-
-
05/18/2026
Imogen Mansfield
Cantor Fitzgerald
Buy
Initiated
-
-
05/18/2026
Imogen Mansfield
Cantor Fitzgerald
Buy
Initiated
-
-
05/18/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
53.74M
-
-
-
Cost of goods sold
3.32M
3.22M
4.26M
5.15M
Cost of revenue
3.32M
3.22M
4.26M
5.15M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.54M
4.50M
4.86M
5.51M
Operating expense
4.54M
4.50M
4.86M
5.51M
Total operating expenses
7.86M
7.72M
9.12M
10.66M
Operating income
45.88M
-7.72M
-9.12M
-10.66M
Other non operating income
-12.00K
-79.00K
73.00K
238.00K
EBT including unusual items
57.73M
-7.61M
-8.95M
-8.92M
EBT excluding unusual items
46.07M
-7.61M
-8.80M
-8.92M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
57.73M
-7.61M
-8.95M
-8.92M
Net profit margin
107.43%
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
400.00K
392.00K
446.00K
1.50M
Interest expense
-200.00K
-200.00K
-200.00K
-
Net interest expenses
200.00K
192.00K
246.00K
1.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
45.97M
-7.63M
-9.03M
-10.58M
Gain or loss from assets sale
-11.74M
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps